Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

580 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Drug Evaluation during the Covid-19 Pandemic.
Rome BN, Avorn J. Rome BN, et al. Among authors: avorn j. N Engl J Med. 2020 Jun 11;382(24):2282-2284. doi: 10.1056/NEJMp2009457. Epub 2020 Apr 14. N Engl J Med. 2020. PMID: 32289216 No abstract available.
Public funding for transformative drugs: the case of sofosbuvir.
Barenie RE, Avorn J, Tessema FA, Kesselheim AS. Barenie RE, et al. Among authors: avorn j. Drug Discov Today. 2021 Jan;26(1):273-281. doi: 10.1016/j.drudis.2020.09.024. Epub 2020 Oct 1. Drug Discov Today. 2021. PMID: 33011345 Free PMC article. Review.
Origins and Ownership of Remdesivir: Implications for Pricing.
Lee CC, Darrow JJ, Avorn J, Kesselheim AS. Lee CC, et al. Among authors: avorn j. J Law Med Ethics. 2020 Sep;48(3):613-618. doi: 10.1177/1073110520958890. J Law Med Ethics. 2020. PMID: 33021169 No abstract available.
The Future of Drug-Pricing Transparency.
Feldman WB, Rome BN, Avorn J, Kesselheim AS. Feldman WB, et al. Among authors: avorn j. N Engl J Med. 2021 Feb 11;384(6):489-491. doi: 10.1056/NEJMp2033734. Epub 2021 Jan 13. N Engl J Med. 2021. PMID: 33440087 No abstract available.
580 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page